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=0:095) or disease stage (P =0:31). Nineteen of the 85 patients had 
prior treatment with surgery and both their average vagina scores (P 
=0:025) and maximum vagina (P =0:045) scores were significantly 
lower than those for non-surgically treated patients. Similarly for 
sexual dysfunction scores, the averages scores (P =0:042) for those 
patients who had prior surgery were lower than those who had no 
surgery and the maximum score was significantly different (P =0:027). 
Statistical analysis of data: The mean and maximum subjective sexual 
function and satisfaction score and average objective score were 
highest in patients in which gap between treatment and interview was 
11 years but non significant. The objective mean score VG (Vagina) 
was highest (0.6444) in patients who were interviewed after 11 years 
of treatment and maximum score (0.80) was highest in patients in 
which gap between treatment and interview was 10 years. Average 
overall LENT SOMA score was highest in patients in which gap between 
treatment and interview was 11 years. (p value- 0.705) 
Conclusions: The LENT SOMA system was acceptable and feasible to 
use and gave us an insight into the morbidity in our patients. Since it 
is one of few studies in India on late morbidity in treated patients of 
carcinoma cervix, it will also help us to develop effective 
management plans to reduce the post treatment symptoms and 
improve quality of life.  
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Purpose/Objective: Rectal volume change is a proved source of 
variation during external beam radiotherapy. Vaginal cuff 
brachytherapy is one of the most widely and settle brachytherapy 
procedures wordwile. Some groups advocate aprevious rectum 
cleansing, although no studies exist analysing the consequences of 
rectal distention during vaginal cuff brachytherapy. The aim of our 
study was to define how the type of rectal content affects its 
dosimetric values. 
Materials and Methods: CT sets (337) derived from 92 patients 
treated with vaginal cuff brachytherapy were re-segmented and re-
planned for study purpose under the same parameters. Rectum DVH 
values were extracted and parametric and non-parametric analysis 
was carried out according to the rectal content. Tukey HSD test was 
used for post-hoc comparisons. 
Results: Kruskal-Wallis (D5cc, D10cc) and ANOVA (Dmax, D0.1cc, 
D2cc) tests showed significant differences among empty rectums, 
rectums with feces, and rectums with gas pockets (all p<.00001). 
  
Conclusions: Gas pockets are a source of rectal dose increase during 
vaginal cuff brachytherapy. Manoeuvers adressed to reduce it, like 
rectal tubes or rectum cleansing, could diminish rectal doses and 
secondary toxicity. Avoiding contrast rectal enemas that increase 
rectal volumes could also be of worth is such direction.  
   
 ELECTRONIC POSTER: CLINICAL TRACK: SARCOMA  
  
EP-1104   
Treatment of cutaneous angiosarcoma of the face: efficacy of 
combined chemo-radiotherapy. 
V. Ravo1, N. Apice2, S. Falivene3, R. Di Franco3, A. De Chiara4, G. De 
Palma5 
1P.O. Ascalesi ASL NA1, UOC Radioterapia, Napoli, Italy  
2INT Pascale, UOC Oncologia, Napoli, Italy  
3Seconda Università di Napoli, UOC Radioterapia, Napoli, Italy  
4INT Pascale, UOC Anatomia Patologica, Napoli, Italy  
5INT Pascale, UOC Radioterapia, Napoli, Italy  
 
Purpose/Objective: Cutaneous angiosarcoma is a rare form of soft-
tissue sarcomas (STS). It is aggressive, malignancy with a poor 
prognosis. 
Materials and Methods: We present the case of a male, 60-years-old, 
with angiosarcoma (AS) spreading over the entire surface of the nose. 
The lesions became swollen and thick. Surgery was excluded because 
it was considered highly invasive with poor cosmetic result. The 
patient was treated with 6 cycles of chemotherapy with taxol 80 
mg/mq at the day 1,8,15 every 28 days. Than the patient was treated 
with 3D Conformal Radiotherapy with the total dose of 50 Gy in 25 
fractions of 2Gy. After that, other 3 cycles of chemotherapy with 
taxol 80 mg/mq at the day 1, 8, 15 every 28days.  
Results: We obtained a complete response. At the last follow-up (40 
months after treatment) the patient was in good general clinical 
condition, without signs of late toxicity due to radiotherapy or 
chemotherapy; all lesions disappeared and all exams were still 
negative.  
Conclusions: Our analysis shows that chemotherapy and radiotherapy 
can be delivered in safety and can be well tolerated with a low grade 
of toxicity and good results in term of local control and complete 
response, also if the location of the AS is uncommon. It was obtained 
an excellent aesthetic result with improvement of quality of life of 
the patient. 
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Purpose/Objective: The longevity of the population makes possible 
the diagnosis of lung neoplasms in elderly patients emerging 
controversies and doubts about the implementation of aggressive 
treatments that damage their vital activity. The existence of 
comorbidities in this population discards the surgical option in many 
cases, with the options of radiotherapy and/or chemotherapy as 
radical treatments, but with doubts about toxicity and benefit.The 
aim of our study is to examine the tolerance of elderly patients 
diagnosed with lung cancer at different stages when subjected to 
external radiotherapy 
Materials and Methods: We analyzed a group of 46 patients diagnosed 
with lung cancer aged over 70 years and stages I-IV, treated with 
conformal 3D external radiotherapy. 24 patients received total doses 
ranged from 45-60Gy with conventional fractionation (1.8-2 Gy/fx); 
hypofractionation schemes (total doses 15-60Gy) were used in 22 
cases.Acute toxicity was evaluated with RTOG/EORTC scales. 
Pulmonary toxicity ([P], dyspnea) and esophageal ([E], 
dysphagia/odinophagia) were taken as causes of pause or 
discontinuing treatment 
Results: 28 patients did not develop any toxicity. 13 patients had 
grade 1 (lung, esophageal or both); 3 patients developed grade 2. In 2 
patients, we could not evaluate because definitive interruption 
(complications of neoplasm). Only 3 cases presented pause of 
treatment, restarting again after clinical improvement (all of them 
with conventional fractionation. One of them without toxicity because 
voluntary decision of the patient) According to fractionation: 19 
patients with hypofrationation (86.4%) did not develop acute toxicity. 
In conventional group, 14 patients (61%) had some degree of toxicity. 
Mediastinum was included as treatment volume in 28 patients. When 
it was irradiated, 50% of cases had some degree of toxicity ( 1 or 2), 
with treatment discontinued in 2 patients. When mediastinal 
exclusion, 83% of patients completed treatment without acute 
toxicity.  
Conclusions: Globally we observed that tolerance to external beam 
radiation therapy in elderly patients is acceptable, and no different 
from that to be found in younger patient groups subjected to the 
same treatment regimens. The application of external radiation 
therapy in elderly patients must be taking into account in the cases of 
lung cancer, and should not be discarded as a therapeutic option. 
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Temporary interruption of treatment in three patients is not a high 
rate of pauses that may affect the outcome of cancer treatment (local 
control of the disease). It also shows the small negative effect of 
these treatments during application and good clinical acceptance in 
groups of elderly patients. Definitive interruption of treatment 
occurred in only 2 patients. They were not as a result of acute toxicity 
produced during radiotherpay, which reaffirms the option of external 
radiation therapy as a treatment in elderly based on toxicity criteria 
and/or fragility of the patient.Hypofractionation may be a valid 
treatment regimen in elderly patients with comorbidities. 
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Purpose/Objective: To compare orthovoltage X-ray therapy (OXRT) 
and standard treatment for reducing pain in knee OA.  
Materials and Methods: Twentyone patients having Grade 1 of knee 
joints OA evaluated by Kellgren Lawrence Score, were prospectively 
randomized to OXRT (n=11) or standard treatment consisting of 
combined Chondroitin (CS) and Glucosamine Sulfates (GS) medicine 
'Theraflex' and non-steroid anti-inflammatory drug Ketoprofen (n=10). 
Dose prescription for OXRT (XStrahl-200, Gulmay Medical Inc., USA) 
was 4,8 Gy in 10 fractions for 3.5 weeks. Theraflex was given 1 dose, 
containing CS 400 mg and GS 500 mg 3 times per day during 3 weeks in 
combination with Ketoprofen 100 mg 3 times a day. Supportive 
treatment consisting of Theraflex twice daily and Ketoprofen 100 mg 
up to 2 times a day begun from the fourth week during 3 months. The 
pain severity was evaluated by visual-analogue scale (VAS). The 
comparative analysis, considering the values in VAS being continuous, 
was performed using Mann-Whitney test. 
Results: Median age of patients in OXRT group was 53.2 (SD, 2.80) and 
Theraflex group 55.1 (SD,3.2). The proportions of males were 45.5% 
and 40.0% for OXRT and Theraflex groups respectively. The 
distribution on initial characteristics was equal. Initially, the pain 
severity in OXRT group was 7.3 (95% CI, 6.6-7.9) and 7.5 (95% CI, 6.8-
8.3) for the patients of Theraflex group. After 3 months of follow-up 
the pain level by VAS has been reduced by 4,3 (Q1 3.0 - Q3 5.6) and 
2,4(Q1 0.6 - Q3 3.3), ?=0.006, U=17.00 among patients of OXRT and 
Theraflex groups, respectively. 
Conclusions: Orthovoltage X-ray therapy allows decreasing 
significantly pain after 3 month. The evolution of cartilage thickness 
and long-term safety should be measured further.  
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Purpose/Objective: To assess the efficacy and safety of neoadjuvant 
chemoradiotherapy in elderly patients with resectable oesophageal 
carcinoma by a systematic review. 
Materials and Methods: Medline, Embase, ISI Web of Knowledge, 
Cochrane Library and China Biological Medicine Database were 
systematically searched in September 2012. Studies comparing the 
outcomes of neoadjuvant chemoradiotherapy or surgery only for 
elderly patients with oesophageal carcinoma were included without 
language restriction. The minimum threshold age used to define the 
elderly was 60 years. The primary outcomes were long-term survival, 
postoperative mortality and complication. All statistical analyses were 
undertaken in Review Manager 5.1 and random effect model was used. 
Results: Out of the initially 144 hits, four studies of 1221 patients (1 
randomized controlled trial, 3 cohort studies) were included. Meta-
analyses based on 3 studies suggested that neoadjuvant 
chemoradiotherapy was not associated with significant improvement 
in disease-free survival (HR=1.08, 95%CI: 0.91-1.28; p=0.38) and 
overall survival (HR=1.12, 95%CI: 0.94-1.33; p=0.19) than surgery 
alone in elderly patients. The 3 years survival rate was 40% vs. 34% in 
neoadjuvant group and surgery alone group, while 5 years survival 
rate was 18% vs. 20%, respectively. No significant survival difference 
was found (p>0.05). And there was also no significantly difference in 
postoperative mortality and major complications (including 
respiratory diseases, cardiovascular diseases, renal failure, and 
anastomotic leak) based on 3 studies. Quality of life was reported in 
one study which showed no significant difference  between two groups 
except for less hospital discharge in neoadjuvant group. 
Conclusions: Comparing with surgery alone, neoadjuvant 
chemoradiotherapy didn't show significantly survival benefit in the 
elderly with oesophageal carcinoma. Though studies were few in 
number, the current available evidence prompted that the elderly 
may get less benefit from neoadjuvant chemoradiotherapy than 
younger. The effect of neoadjuvant chemoradiotherapy for the elderly 
esophageal cancer is still unproven, more clinical studies are needed 
for the definite results.If possible, additional subgroup analysis by 
different ages in randomized controlled trials may help. 
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Purpose/Objective: For several decades, radiotherapy (RT) has been 
widely used to treat metastatic spinal tumors. This study was designed 
to assess the feasibility and early clinical outcome of high dose RT to 
treat such tumors, using helical tomotherapy (HT). 
Materials and Methods: Between June 2009 and December 2011, 51 
sites in 36 patients were treated with high dose RT using HT for spinal 
metastasis. Treatment outcomes and dosimetric analyses of spinal 
cord were retrospectively evaluated.  
Results: Median follow-up was 11.5 months (range, 6–34.6) for 
surviving patients. The median fractional dose and the number of 
fractions in the primary HT arm were 2,700 cGy and 3 fractions, 
respectively. Actuarial 6-month local control rates was 85.7%, and 
symptomatic vertebral compression fractures developed in five 
patients after median 4.2 months. Among 13 patients with 19 
metastatic sites who showed pre-treatment impairment in neurologic 
function, five patients (with seven sites) in whom symptoms were mild 
showed improvement in neuronal function. The median pre-treatment 
VAS score of 7 decreased to a median of 3 after HT (P < 0.001) at 
median 1 month (range, 0.5-3.2). No significant morbidity developed 
during follow-up except for one grade 3 esophagitis.  
Conclusions: The use of HT to treat metastatic spinal tumors appears 
to be both safe and reliable in terms of local tumor control and early 
pain relief. Local progression and the risk of compression fracture in 
patients with pre-existing spinal instability remain as the principal 
factors of limiting improved clinical and functional outcomes. Optimal 
dose fractionation schemes and appropriate patient selections are 
required to achieve better outcomes with high dose RT using HT. 
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Purpose/Objective: Most malignant lymphomas are effectively 
treated by chemotherapy, but some of them relapse and become 
refractory. Treatment of relapsed chemoresistant or refractory 
lymphoma is difficult in many cases and salvage chemotherapy with or 
without autologous stem cell transplant is not always effective. Best 
supportive care is often chosen for such patients; however, palliative 
radiotherapy (RT) is thought to be very useful for some cases. The aim 
of this study was to analyze the treatment outcomes of patients who 
received palliative RT for relapsed or refractory malignant lymphoma. 
Materials and Methods: From 2008-2012, 160 patients with malignant 
lymphoma were treated at the Department of Radiation Oncology in 
our institute. Among them, 20 patients (12.5%) were referred with 
palliative intent, consisting of 17 aggressive lymphomas (13 diffuse 
large B-cell lymphomas and 4 other lymphomas) and 3 indolent 
lymphomas. Six patients had a bulky tumor and 10 patients showed 
multiple masses. The treatment outcomes of palliative RT were 
retrospectively analyzed. 
Results: The median age at the time of RT was 60 years old (range: 
42-92), and 13 patients (65%) were male. Three patients died during 
treatment. The median follow-up from RT was 3 months(range: 0.75-
19). Overall response rate was 94% (complete response: 36%, partial 
response: 58%). The median overall survival was 3 months (range: 
0.75-19). In RT for 48 sites of 20 patients, median dose of treatment 
was 34 Gy (range: 4-50). Nineteen patients (95%) showed a significant 
response to RT (pain relief, prevention of neurological symptoms, 
